Published date: 14 September 2021
Last edited date: 3 February 2023
Closed future opportunity - This means that a potential contract has passed its approach to market date. A buyer can choose to consider any supplier interest or convert this notice into an opportunity ready for live procurement.
Contract summary
Industry
Immunoglobulins - 33651520
Location of contract
England, Scotland, Northern Ireland, Isle of Man, Channel Islands
Value of contract
£526,598,540
Procurement reference
CM/PHS/21/5647/W
Published date
14 September 2021
Approach to market date
1 August 2023
Contract start date
1 January 2024
Contract end date
30 June 2025
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
Human Normal Immunoglobulin & Anti-D Immunoglobulin
The purpose of this 'future opportunity' notice is to indicate that a live 'opportunity' may be published at a future date. However, any existing 'live' framework agreement may be subject to an extension up to the maximum extension period allowed.
More information
Spend profile
| Financial year | Budget |
|---|---|
| 2023/2024 | £87,766,423 |
| 2024/2025 | £351,065,694 |
| 2025/2026 | £87,766,423 |
About the buyer
Contact name
Kerry Smith
Address
Commercial Medicines Unit - NHS England
2nd Floor, Rutland House
Runcorn
WA7 2ES
England
Share this notice
Approach to market date: 1 August 2023
All content is available under the
